The U.S. Food and Drug Administration (FDA) has issued its report regarding a voluntary nationwide recall by Vitruvias Therapeutics, Inc. of one lot of Thyroid Tablets, USP 30 mg. Testing of batch stability and routine assay established that the impacted lot poses a risk for superpotency—the tablets contain higher active thyroid hormone concentrations than stated on the label. Excess active hormones from ingesting superpotent thyroid pills raises a Vitruvias Therapeutics Hyperthyroidism Risk Recall risk to a new level because it can push patients with an adequately treated hypothyroid on this medication into overt, acute, or subclinical hyperthyroidism.
| Recall Parameter | Details & Specifications |
| Product Description | Thyroid Tablets, USP 30 mg (porcine-derived T4 & T3) |
| Recalling Firm | Vitruvias Therapeutics, Inc. (Auburn, AL) |
| National Drug Code (NDC) | 69680-166-00 |
| Affected Lot Number | 504950 |
| Expiration Date | 9/30/2026 |
| Distribution Window | January 31, 2025 – September 30, 2025 |
| Units Released / Sold | 3,655 units released / 1,955 units sold nationwide |
| Reason for Recall | Potential product superpotency |
| FDA Class / Status | Voluntary nationwide recall at consumer level |
What Caused the Recall and Why Superpotency Matters
Thyroid Tablets, USP are prepared from desiccated porcine (pig) thyroid. Natural desiccated thyroid (NDT) is different than other single-hormone synthetic treatments like levothyroxine ($$T_4$$). Because $T_3$ is four times more effective weight-for-weight on metabolic processes than $T_4$, and acts rapidly, small differences in dose can have major clinical effects.
Lot is classified superpotent when the active pharmaceutical ingredients (API) are above the limits set forth by USP assay testing. Using higher dose pills gives an unnecessary overdose of thyroid hormone in each daily dosage, practically giving a drug-induced hyperthyroidism (thyrotoxicosis).
Clinical Implications of the Vitruvias Therapeutics Hyperthyroidism Risk Recall
The oral administration of superpotent thyroid hormone tablets results in various hypermetabolic responses involving multiple organ systems. Although tolerance to wide-ranging clinical signs differ between individuals with differing baseline thyroid function and other comorbidities, the establishment of systemic exposure leading to excess hormone can present as specific cardiovascular, neurological and metabolic features.
- Cardiovascular: Increases in $T_3$ and $T_4$, both augmenting cardiac output and increase sensitivity to beta-adrenergic stimulation, sinus tachycardia, palpitations, hypertension; can provoke chest tightness or A-Fib.
- Hypermetabolism & Temperature Regulation: Basal metabolic rate is met with polyphagia which causes unintentional weight loss, as well as significant heat intolerance associated with profuse sweating.
- Neuromuscular & Central Nervous System Effects: Fine muscle tremors, progressive muscle weakness, high fatigue leading to insomnia, acute anxiety and irritability may occur in the patient.
Vulnerable Populations at Heightened Risk
Despite the problems associated with hyperthyroidism in any patient, certain populations suffer adverse complications when they are overdosed for long periods of time with superpotent thyroid formulations:
- Elderly Table 114 Thyrotoxicosis in the Elderly Patients: Older adults show greater predilection for thyroid-driven cardiac events. These include angina, severe hypertension, cardiac decompensation or life-threatening arrhythmias (e.g. atrial fibrillation) as a result of excess thyroid hormone production.
- Pregnant Women: Over-treatment of hypothyroidism during pregnancy modifies systemic vascular resistance and uterine blood flux. It raises the risk of maternal hypertension, gestational hypertension, spontaneous abortion, premature birth and low-birth-weight babies.
- Infant and childhood: Regulation of thyroid in paediatric population is very important for neurological and somatic growth. F) Hyperpotency can cause earlier epiphyseal growth plate closure, impair central nervous system maturation, and result in developmental changes..
Action Steps for Patients and Healthcare Providers
If you or a family member take Thyroid Tablets, USP 30 mg, follow these steps to manage your medication safety:
- Check your bottle: Look for NDC 69680-166-00 with Lot Number 504950 and expiry date 9/30/2026
- Do NOT Stop Medication Cold Turkey: Thyroid replacement therapy should NOT be stopped cold turkey as this will put the patient into rapid hypothyroidism with overwhelming fatigue, brain fog, worsening cold intolerance and extreme metabolic slowing.
- Reach Out to Your Healthcare Practitioner Right Away, Seek a different lot or replacement prescription (synthetic levothyroxine or non-affected NDT brand) before throwing away your bottle.
- Contact Vitruvias Therapeutics: For recall questions, contact Aspidion Therapeutics at (256) 239-9373 (Monday through Friday, 9 AM to 5 PM CT) or safety@vitruvias.com.
- Report Symptoms of Superpotency to MedWatch: Individuals who experienced symptoms consistent with superpotency should report them directly to the FDA MedWatch Adverse Event Reporting program by filling out a form online or calling 1-800-332-1088.
Frequently Asked Questions (FAQs)
Q: What is the Vitruvias Therapeutics Hyperthyroidism Risk Recall?
A: It is a nationwide voluntary recall initiated by Vitruvias Therapeutics, Inc. for one lot (Lot 504950) of Thyroid Tablets, USP 30 mg. The product was recalled due to lab results indicating potential superpotency, which can deliver higher-than-prescribed hormone levels and induce hyperthyroidism.
Q: How do I know if my thyroid medication is part of the recall?
A: Look at the product label printed on your prescription container. Use, NDC 69680-166-00 Lot Number 504950 Expiration Date: 9/30/2026 If these numbers match, your medicine is part of the recall.
Q: What symptoms should I watch for if I took the recalled lot?
A: Overactive thyroid (hyperthyroidism): rapid or irregular heartbeat, chest pain, high blood pressure, heat intolerance; unintentional weight loss; muscle weakness in the upper arms and thighs; anxiety or nervousness; extreme fatigue (tired all the time); shaking hands and fingers.
Q: Should I stop taking my thyroid pills immediately if they are from Lot 504950?
A: Absolutely not. Your doctor and the FDA will warn you that stopping your thyroid therapy cold is a to-be-avoided experience. Ask your provider or pharmacist about getting a safe, unaffected replacement prescription so you can keep your hormone levels stable.
Q: Has anyone reported adverse health effects from this recall?
A: As of the time of the official recall announcement, Vitruvias Therapeutics had not received any unsolicited reports of adverse events associated with Lot 504950. But recall was done on precautionary basis to avoid any incident with the customers.
Navigating Medication Safety with Confidence
The importance of tracking official safety notices: Timely action in response to a recall; Pharmaceutical recalls Logging lot numbers from biopsy-derived Porcine natural desiccated thyroid (NDT) tablets is a hedge against dangerous human error, & keeping open communication with your dispensing pharmacy is completely essential. When there are discrepancies in product potency, as is demonstrated with superpotency, you should consult your doctor to ensure that your treatment plan remains within the limits of cardiac or metabolic adaptation.
Read More: How to Lower Resting Heart Rate: Simple Lifestyle Changes
